{
  "resourceType" : "MedicinalProductDefinition",
  "id" : "mp367b9089c0743a2330f4c6e82b40ee41",
  "meta" : {
    "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: MedicinalProductDefinition</b><a name=\"mp367b9089c0743a2330f4c6e82b40ee41\"> </a><a name=\"hcmp367b9089c0743a2330f4c6e82b40ee41\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource MedicinalProductDefinition &quot;mp367b9089c0743a2330f4c6e82b40ee41&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-MedicinalProductDefinition-uv-epi.html\">MedicinalProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi/#/</code>/EU/1/16/1157/002</p><p><b>type</b>: Medicinal Product <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-medicinal-product-type.html\">Medicinal Product Type</a>#MedicinalProduct)</span></p><p><b>domain</b>: Human use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-medicinal-product-domain.html\">Medicinal Product Domain</a>#Human)</span></p><p><b>status</b>: active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>indication</b>: Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.</p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072084)</span></p><p><b>classification</b>: insulin glargine and lixisenatide <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-WC.html\">WHO ATC</a>#A10AE54)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen</p><p><b>type</b>: Full name <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000001)</span></p><blockquote><p><b>part</b></p><p><b>part</b>: Suliqua</p><p><b>type</b>: Invented name part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000002)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: Insulin glargine, Lixisenatide</p><p><b>type</b>: Scientific name part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000003)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: 100 units/ml + 50 ug/ml</p><p><b>type</b>: Strength part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000004)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: Solution for injection</p><p><b>type</b>: Pharmaceutical dose form part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000005)</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td>Denmark <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#DK)</span></td><td>Denmark <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#DK)</span></td><td>English <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html\">Tags for the Identification of Languages</a>#en)</span></td></tr></table></blockquote></div>"
  },
  "identifier" : [{
    "system" : "https://spor.ema.europa.eu/pmswi/#/",
    "value" : "EU/1/16/1157/002"
  }],
  "type" : {
    "coding" : [{
      "system" : "http://hl7.org/fhir/medicinal-product-type",
      "code" : "MedicinalProduct",
      "display" : "Medicinal Product"
    }]
  },
  "domain" : {
    "coding" : [{
      "system" : "http://hl7.org/fhir/medicinal-product-domain",
      "code" : "Human",
      "display" : "Human use"
    }]
  },
  "status" : {
    "coding" : [{
      "system" : "http://hl7.org/fhir/publication-status",
      "code" : "active",
      "display" : "active"
    }]
  },
  "indication" : "Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.",
  "legalStatusOfSupply" : {
    "coding" : [{
      "system" : "https://spor.ema.europa.eu/rmswi",
      "code" : "100000072084",
      "display" : "Medicinal product subject to medical prescription"
    }]
  },
  "classification" : [{
    "coding" : [{
      "system" : "http://www.whocc.no/atc",
      "code" : "A10AE54",
      "display" : "insulin glargine and lixisenatide"
    }]
  }],
  "name" : [{
    "productName" : "Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen",
    "type" : {
      "coding" : [{
        "system" : "https://spor.ema.europa.eu/lists/220000000000",
        "code" : "220000000001",
        "display" : "Full name"
      }]
    },
    "part" : [{
      "part" : "Suliqua",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/lists/220000000000",
          "code" : "220000000002",
          "display" : "Invented name part"
        }]
      }
    },
    {
      "part" : "Insulin glargine, Lixisenatide",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/lists/220000000000",
          "code" : "220000000003",
          "display" : "Scientific name part"
        }]
      }
    },
    {
      "part" : "100 units/ml + 50 ug/ml",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/lists/220000000000",
          "code" : "220000000004",
          "display" : "Strength part"
        }]
      }
    },
    {
      "part" : "Solution for injection",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/lists/220000000000",
          "code" : "220000000005",
          "display" : "Pharmaceutical dose form part"
        }]
      }
    }],
    "usage" : [{
      "country" : {
        "coding" : [{
          "system" : "urn:iso:std:iso:3166",
          "code" : "DK",
          "display" : "Denmark"
        }]
      },
      "jurisdiction" : {
        "coding" : [{
          "system" : "urn:iso:std:iso:3166",
          "code" : "DK",
          "display" : "Denmark"
        }]
      },
      "language" : {
        "coding" : [{
          "system" : "urn:ietf:bcp:47",
          "code" : "en",
          "display" : "English"
        }]
      }
    }]
  }]
}